Procept BioRobotics initiated with an Outperform at Leerink

Leerink analyst Mike Kratky initiated coverage of Procept BioRobotics with an Outperform rating and $37 price target. The firm notes that BPH presents a large market with significant unmet need, as the progressive nature of BPH and side-effects from current treatment options can make Aquablation a go-to option, the analyst tells investors in a research note. The increase in surgeon base penetration and utilization is expected to drive high double-digit growth, leading to the firm’s expectation of 48% revenue CAGR between 2022-2028.